NCT06200376招募中1 期
A Clinical Study of Safety and Efficacy of T3011 Administered Via Intraperitoneal Injection as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Adverse event
研究概览
简要总结
This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intraperitoneal administration of T3011 at different doses in the treatment of malignant ascites induced by advanced colorectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female age ≥ 18 years and ≤ 75 years at the time of informed consent.
- •Histologically or cytologically confirmed advanced unresectable or metastatic colorectal cancer;
- •Anticipated life expectancy ≥3 months
- •Associated with medium amount of malignant ascites (defined as the amount of ascites ≥3cm by B ultrasonography in lying position accompanied by clinical symptomes like abdonimal distension and cytology tests possitive for tumor in ascites); No paracentesis performed with 28 days before first dosing; and the ascites can not be controlled by SOC according to PI judgement.
- •ECOG performance status 0-2 (including threshold);
- •Weight ≥40kg
- •Hematology:
- •White blood cell (WBC) ≥ 3.0×10^9/L;
- •Neutrophil (ANC) ≥ 1.5×10^9/L;
- •Platelet (PLT) ≥ 75×10^9/L;
- •Hemoglobin (Hb) ≥ 8.0g/dL
- •Hepatic and renal function:
- •Total bilirubin ≤ 1.5 × ULN;
- •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 × ULN for patient without liver metastasis, ≤ 5 × ULN for patients with liver metastasis;
- •Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL/min as determined by the Cockcroft-Gault equation;
- •Abumin≥30 g/L
- •Coagulation:
- •INR≤1.5 x ULN;
- •APTT≤1.5 x ULN;
- •For women of childbearing potential (WCBP), serum pregnancy test should be negative within 14 days before dosing. WCBP patients, as well as male patients with partners of WCBP, should consent to use at least one medically approved contraceptive method (e.g. surgical sterilization, oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicides) during the study and for at least 6 months after the last dosing;
- •Willingness to attend this study, to sign informed consent, to have good compliance, and to cooperate with follow-up visit.
排除标准
- •Previously diagnosed with decompensated cirrhosis, and with portal vein and branch involvement or cancer embolus;
- •Pregnant or lactating, or plan to pregnant or give birth during the trial;
- •Persistent or active infection that are not controlled by treatment including but not limited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ;
- •Patients with imageological confirmed brain metastasis or brain metastasis history (except patients with stable disease within 3 months before screening and not require systemic glucorticoid therapy according to PI), pia meningeal disease, spinal cord compression;
- •Autoimmune disease or related symptoms, or previously suffered from autoimmune disease;
- •History of splenectomy or organ transplantation;
- •Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC, T3011), gene therapy, cellular therapy or tumor vaccines;
- •Requires oral or intravenous therapy against herpes virus (including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs (eg. external use) are allowed;
- •Patients are scheduled to receive other therapy against malignant ascites (including but not limited to chemotherapy, target therapy, immunotherapy), and the best supportive treatment for malignant ascites is permitted (e.g., albumin supplements, etc.);
- •Patients with a known psychiatric disorder that would interfere with cooperation with the requirements of the trial;
- •History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent;
- •History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients for T3011;
- •History or evidence of high risk cardiovascular disease, including but not limited to:
- •Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female);
- •Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug;
- •Coronary angioplasty or stent implantation within 6 months prior to first administration of the experimental drug;
- •Rating of heart function as defined by the New York Heart Association (NYHA) standards>grade II; Cardiac valve abnormalities recorded by echocardiography (≥ grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mild regurgitation/stenosis) were admitted, but subjects with moderate valve thickening were excluded;
- •Left ventricular ejection fraction (LVEF) < the center lower limit. If no lower limit existed, LVEF<50%;
- •Poor blood pressure control after antihypertensive treatment (i.e. systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);
- •History of another malignant tumor, except the following:
- •Undergo potentially curative therapy and for ≥5 years prior to the first dose of study treatment and no malignancies with known active disease and low potential recurrence risk;
- •Adequately treated non-melanoma skin cancer or lentigo with no evidence of malignancy;
- •Adequately treated carcinoma in situ without evidence of disease;
- •Received live and attenuated vaccines within 4 weeks prior to initiation of study treatment, or plan to be vaccined during the study;
- •Previous history of immunotherapy induced non-infectious pneumonitis/ interstitial lung disease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-related irAE that can be stably controlled by hormone replacement therapy;
- •Unexplained >38.5℃ fever (except for tumor induced fever judged by PI) occurs during the screening period, baseline period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or patient's efficacy evaluation;
- •Any condition that PI considered may confuse the trial results, interfere with the participant's participation in the trial, or is not in the participant's best interest to participate in the trial, or a history of treatment or laboratory abnormalities, or other ineligibility for enrollment
研究组 & 干预措施
T3011
Experimental
干预措施: T3011 (Drug)
结局指标
主要结局
Adverse event
时间窗: 28 days after EOT
To evaluate the safety of intraperitoneal T3011 in the treatment of patients with malignant intraperitoneal ascites
次要结局
- Time to onset of therapeutic paracentesis(From 4th dosing to disease progression, consent withdraw, death or end of study, assessed up to 24 months)
- Overall response rate (ORR)(From 4th dosing to disease progression, consent withdraw, death or end of study, assessed up to 24 months)
- Disease control rate (DCR)(From 4th dosing to disease progression, consent withdraw, death or end of study, assessed up to 24 months)
- Overall survival (OS)(Up to 24 months)
- Quality of life questionnaire (QLQ-C30)(Up to 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal CancerAdvanced Colorectal CancerNCT06200363West China Hospital15
招募中
1 期
A Clinical Study of T3011 in Subjects With Advanced MelanomaAdvanced MelanomaNCT06214156Shanghai Pharmaceuticals Holding Co., Ltd42
尚未招募
1 期
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerColorectal Cancer MetastaticNCT06283303China Medical University, China8
已完成
不适用
Evaluating the Efficacy and Safety of Treatment With LinearFirm(ULTRAcel Q+) in Temporary Eyebrow LiftingHigh Intensity Focused UltrasoundNCT06457607Jeisys Medical Inc38
招募中
1 期
A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsAdvanced Solid TumorHNSCCEsophagus CancerBreast CancerNSCLCSarcomaNon-melanoma Skin CancerNCT05602792ImmVira Pharma Co. Ltd233